# Reducing Cardiovascular Disease by Combining Smoking Cessation Pharmacotherapy and Behavioural Counseling

> **NCT01623505** · PHASE4 · COMPLETED · sponsor: **Ottawa Heart Institute Research Corporation** · enrollment: 738 (actual)

## Conditions studied

- Smoking Cessation
- Psychiatric Illness

## Interventions

- **DRUG:** Champix
- **DRUG:** Transdermal Nicoderm patch combined with gum or inhaler
- **DRUG:** Transdermal Nicoderm patch

## Key facts

- **NCT ID:** NCT01623505
- **Lead sponsor:** Ottawa Heart Institute Research Corporation
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 738 (ACTUAL)
- **Last updated:** 2017-04-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01623505

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01623505, "Reducing Cardiovascular Disease by Combining Smoking Cessation Pharmacotherapy and Behavioural Counseling". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01623505. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*